EASTONBIOPHARMACEUTICALS(SH:688513) Xin Lang Cai Jing·2025-10-28 06:56Group 1 - The core point of the news is that Yuandong Biopharmaceuticals experienced a stock price increase of 5.47%, reaching 55.30 CNY per share, with a trading volume of 150 million CNY and a turnover rate of 1.58%, resulting in a total market capitalization of 9.762 billion CNY [1] - Yuandong Biopharmaceuticals, established on June 1, 2009, and listed on September 2, 2020, is located in Chengdu, Sichuan Province. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition of Yuandong Biopharmaceuticals includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - According to data from the top ten holdings of funds, Hongde Fund has a significant position in Yuandong Biopharmaceuticals, with its Hongde Medical Innovation Mixed Fund A (012481) holding 27,000 shares, unchanged from the previous period, accounting for 8.53% of the fund's net value, making it the second-largest holding [2] - The Hongde Medical Innovation Mixed Fund A (012481) was established on February 22, 2023, with a latest scale of 14.8031 million CNY. The fund has achieved a return of 41.8% this year, ranking 1877 out of 8155 in its category, and a return of 32.63% over the past year, ranking 2503 out of 8029 [2]